We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+11.3%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$356M
AUM Growth
-$6.71M
Cap. Flow
-$34.6M
Cap. Flow %
-9.71%
Top 10 Hldgs %
92.06%
Holding
21
New
1
Increased
5
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
AKAO
Achaogen Inc
AKAO
+$5.81M
2
IMMU
Immunomedics Inc
IMMU
+$3.78M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$2.91M
4
EPZM
Epizyme, Inc
EPZM
+$2.16M
5
ASND icon
Ascendis Pharma A/S
ASND
+$1.86M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$20.4M
2
BPMC
Blueprint Medicines
BPMC
+$4.76M
3
AIMT
Aimmune Therapeutics
AIMT
+$4.75M
4
LOXO
Loxo Oncology, Inc
LOXO
+$4.61M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$117M 32.7%
1,950,477
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$43.6M 12.24%
2,700,000
+320,633
+13% +$3.78M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$32.6M 9.15%
2,847,130
-95,073
-3% -$1.06M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$30.2M 8.46%
400,000
-67,682
-14% -$4.76M
AIMT
5
DELISTED
Aimmune Therapeutics
AIMT
$28.9M 8.12%
764,824
-147,177
-16% -$4.75M
AKAO
6
DELISTED
Achaogen Inc
AKAO
$25.5M 7.16%
2,375,000
+462,894
+24% +$5.81M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.5B
$13.5M 3.78%
336,264
+51,121
+18% +$1.86M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$12.8M 3.61%
305,187
+10,187
+3% +$393K
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$12.5M 3.52%
998,278
+148,585
+17% +$2.16M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$11.8M 3.32%
278,753
– –
VRNA
11
DELISTED
Verona Pharma
VRNA
$6.27M 1.76%
528,422
-80,429
-13% -$1.04M
WVE icon
12
Wave Life Sciences
WVE
$1.14B
$5.7M 1.6%
162,347
-700,980
-81% -$20.4M
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
$5.52M 1.55%
600,000
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$744M
$5.25M 1.47%
212,950
-50,000
-19% -$1.22M
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.85M 0.8%
+105,706
New +$2.91M
FBRX icon
16
Forte Biosciences
FBRX
$1.57B
$1.52M 0.43%
396
-386
-49% -$1.54M
PACB icon
17
Pacific Biosciences
PACB
$432M
$1.18M 0.33%
447,520
-702,480
-61% -$2.46M
ARGX icon
18
argenx
ARGX
$54.6B
– –
-176,500
Closed -$3.99M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-100,000
Closed -$4.5M
DERM
20
DELISTED
Dermira, Inc.
DERM
– –
-43,071
Closed -$1.16M
LOXO
21
DELISTED
Loxo Oncology, Inc
LOXO
– –
-50,000
Closed -$4.61M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2017 Portfolio in Review

As of Q4 2017, Foresite Capital Management III held 21 positions worth $356M, down 1.8% from $363M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Foresite Capital Management III withdrew a net $34.6M in Q4 2017, closing 4 positions and reducing 8 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $4.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 50% a quarter earlier.

Against the trend, Foresite Capital Management III opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $2.85M.

  • Foresite Capital Management III's largest Q4 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 105,706 shares worth $2.85M.
  • Foresite Capital Management III added most to Achaogen Inc in Q4 2017, an estimated $5.81M increase.
  • Foresite Capital Management III's biggest Q4 2017 reduction was Wave Life Sciences, cutting an estimated $20.4M.
  • Foresite Capital Management III fully exited Loxo Oncology, Inc in Q4 2017, selling an estimated $4.61M.
  • Foresite Capital Management III's ten largest holdings make up 92% of its $356M portfolio in Q4 2017.
  • Foresite Capital Management III opened 1 new position and closed 4 in Q4 2017.
  • Foresite Capital Management III's portfolio value fell 1.8% quarter-over-quarter to $356M.

Based on Foresite Capital Management III's 13F filing for Q4 2017, filed 13 Feb 2018.